LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Enzastaurin | 0.04 | uM | LJP5 | 3 | D18 | 72 | hr | 868 | 3895 | 3440 | 1.1322 | 1.1290 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 1 | D17 | 72 | hr | 868 | 3287 | 3286 | 1.0002 | 1.0002 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 2 | D17 | 72 | hr | 868 | 3270 | 3505 | 0.9328 | 0.9321 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 3 | D17 | 72 | hr | 868 | 3700 | 3440 | 1.0755 | 1.0746 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 1 | D16 | 72 | hr | 868 | 3563 | 3286 | 1.0842 | 1.0860 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 2 | D16 | 72 | hr | 868 | 3208 | 3505 | 0.9152 | 0.9139 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 3 | D16 | 72 | hr | 868 | 3656 | 3440 | 1.0627 | 1.0622 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 1 | D15 | 72 | hr | 868 | 3654 | 3286 | 1.1119 | 1.1136 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 2 | D15 | 72 | hr | 868 | 3288 | 3505 | 0.9380 | 0.9374 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 3 | D15 | 72 | hr | 868 | 3673 | 3440 | 1.0676 | 1.0670 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 1 | D14 | 72 | hr | 868 | 3555 | 3286 | 1.0818 | 1.0835 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 2 | D14 | 72 | hr | 868 | 3122 | 3505 | 0.8906 | 0.8882 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 3 | D14 | 72 | hr | 868 | 3772 | 3440 | 1.0964 | 1.0949 |
MDA-MB-231 | Enzastaurin | 10 | uM | LJP5 | 1 | D13 | 72 | hr | 868 | 3224 | 3286 | 0.9811 | 0.9802 |
MDA-MB-231 | Enzastaurin | 10 | uM | LJP5 | 2 | D13 | 72 | hr | 868 | 3329 | 3505 | 0.9497 | 0.9494 |
MDA-MB-231 | Enzastaurin | 10 | uM | LJP5 | 3 | D13 | 72 | hr | 868 | 3238 | 3440 | 0.9412 | 0.9399 |
MDA-MB-231 | Palbociclib | 0.04 | uM | LJP6 | 1 | E18 | 72 | hr | 868 | 2687 | 3429 | 0.7834 | 0.7683 |
MDA-MB-231 | Palbociclib | 0.04 | uM | LJP6 | 2 | E18 | 72 | hr | 868 | 2760 | 3652 | 0.7558 | 0.7472 |
MDA-MB-231 | Palbociclib | 0.04 | uM | LJP6 | 3 | E18 | 72 | hr | 868 | 2674 | 3587 | 0.7454 | 0.7326 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 1 | E17 | 72 | hr | 868 | 2447 | 3429 | 0.7135 | 0.6868 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 2 | E17 | 72 | hr | 868 | 2402 | 3652 | 0.6577 | 0.6340 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 3 | E17 | 72 | hr | 868 | 2166 | 3587 | 0.6038 | 0.5631 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 1 | E16 | 72 | hr | 868 | 2125 | 3429 | 0.6196 | 0.5709 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 2 | E16 | 72 | hr | 868 | 1868 | 3652 | 0.5115 | 0.4473 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 3 | E16 | 72 | hr | 868 | 1931 | 3587 | 0.5383 | 0.4778 |